Cytos, OnCore Biopharma deal

OnCore received exclusive, worldwide rights to use Cytos’ virus-like particle (VLP) platform to develop therapies for HBV infection and an option to use the platform to develop up to five more antivirals programs, excluding influenza. Cytos did not receive an upfront payment but is eligible for up to $67 million in milestones for each programs, or a total of $402 million. Cytos also is eligible for up to $120 million in sales milestones, plus up to double-digit royalties. ...